• Tampa General Hospital announced on Thursday that its Cancer Institute earned a three-year accreditation from the Commission on Cancer
• TGH’s Cancer Institute attained accreditation by satisfying 34 quality care requirements as well as a series of other benchmarks including patient quality of life 
• In recent years, TGH’s Cancer Institute expanded to several additional locations, staffed by specially trained physicians, to increase access to cancer care
• Further, the TGH Cancer Institute is rated among the top 10 percent of U.S. hospitals for cancer care, according to U.S. News & World Report’s 2022-2023 rankings.

Tampa General Hospital (TGH) — the primary teaching hospital for the USF Health Morsani College of Medicine — announced on Thursday that its Cancer Institute earned a three-year accreditation from the Commission on Cancer (CoC). 

TGH’s Cancer Institute attained accreditation by satisfying 34 quality care requirements, providing high-quality, patient-centered cancer care via a multidisciplinary approach, and demonstrating a commitment to improving patient outcomes and quality of life for all cancer patients, according to the hospital.

“We set out to build a Cancer Institute of the future that excels in cancer research, clinical investigations, prevention, and control, and we have spent the past several years devoting significant energy and resources and acquiring the brightest talent to bring that vision to life,” said John Couris, president and CEO of TGH. “Our team is tremendously proud of this accreditation, which is a testament to the unparalleled expertise and quality of care we offer our patients and community across the continuum of cancer care services.”

TGH Cancer Institute is rated among the top 10 percent of U.S. hospitals for cancer care, according to U.S. News & World Report’s 2022-2023 rankings.

In recent years, TGH’s Cancer Institute expanded to several additional locations, staffed by specially trained physicians, to increase access to cancer care.

“The TGH Cancer Institute is dedicated to providing the most advanced testing, next-generation research, therapies and treatment, and patient care because we recognize the importance of treating the whole person, not the condition. When fighting cancer, every decision impacts patients’ lives and every advantage needs to be identified,” said Thomas Rutherford, MD, medical director of the TGH Cancer Institute.

TGH also recently established the TGH/USF Health Precision Medicine Biorepository, which collects, catalogs, and stores samples of biological material for medical research.

The biorepository holds donated specimens from patients that researchers, physicians, and scientists can access for scientific study, creating new opportunities to advance research in cancer tumor sequencing and precision medicine.